Skip to main content

Advertisement

Log in

Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, International Vidaza High-Risk MDS Survival Study Group et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

    Article  PubMed  CAS  Google Scholar 

  2. Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndrome. J Clin Oncol 29:516–523

    Article  PubMed  CAS  Google Scholar 

  3. Keating GM (2012) Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukemia. Drugs 72:1111–1136

    Article  PubMed  CAS  Google Scholar 

  4. Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellstrom-Lindberg E, Santini V et al (2010) Effects of azacitidine compared with conventional care regimens in elderly (>75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76:218–227

    Article  PubMed  Google Scholar 

  5. Breccia M, Loglisci G, Salaroli A, Serrao A, Petrucci L, Mancini M, Alimena G (2012) 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. Leuk Lymphoma 53(8):1558–1560

    Article  PubMed  CAS  Google Scholar 

  6. Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F et al (2010) 5-Azacitidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 45:872–876

    Article  PubMed  CAS  Google Scholar 

  7. Lubbert M, Bertz H, Wasch R, Marks R, Ruter B, Claus R, Finke J (2010) Efficacy of a 3-day, low-dose treatment with 5-azacitidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 45:627–632

    Article  PubMed  CAS  Google Scholar 

  8. Ustun C, Kalla A, Farrow S, DeRemer DL, Jilella A (2008) Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation. Am J Hematol 83:825–827

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

All authors declare that they have no conflict of interest to report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Massimo Breccia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breccia, M., Salaroli, A., Serrao, A. et al. Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation. Ann Hematol 92, 1413–1414 (2013). https://doi.org/10.1007/s00277-013-1732-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1732-2

Keywords

Navigation